News
Patients requiring treatment for proteinuria reduction in primary immunoglobulin A (IgA) nephropathy now have a solution, with the FDA's accelerated approval of atrasentan (Vanrafia; Novartis).. 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback